FDA expands recall on blood pressure drug valsartan due to probable carcinogen
The FDA is expanding a recall of a popular blood pressure drug over concern it may contain an unwanted ingredient that can cause cancer. Aurobindo Pharma says it is voluntarily recalling tablets with the ingredient valsartan because it found trace amounts of a substance known as NDEA. Recalls of contaminated valsartan products started in July and involve seven different companies. Dr. Tara Narula joins "CBS This Morning" with more on the latest recall.